Transcatheter aortic valve replacement in cancer patients with chest radiation therapy: Risks and outcomes.

S Saad Farooq (Montefiore Saint Luke's Cornwall Hospital, Newburgh, NY) M Muneeb Khawar (King Edward Medical University, Lahore, Pakistan) U Umad Ali (King Edward Medical University, Lahore, Pakistan) S Syed Abdullah Shah M Mirza Muhammad Hadeed khawar (Services Institute of Medical Sciences, Lahore, Pakistan) A Awon Muhammad (King Edward Medical University, Lahore, Pakistan) H Hannan Saeed (KEMU, Lahore, Pakistan) S Sardar Muhammad Imran Khan (NUMS, Rawalpindi , Pakistan) A Abdul Qadeer M Mobeen Zaka Haider (West Virginia University, Morgantown, WV) M Mohammad Hamza (Albany Medical Center, Aldan, Pennsylvania, United States) R Robert W. Kirchoff (Mayo Clinic Hospital, Pheonix, AZ)

Abstract

e24020 Background: Transcatheter aortic valve replacement (TAVR) is a widely adopted treatment for severe aortic stenosis, but outcomes in cancer survivors with prior chest radiation therapy (C-XRT) remain uncertain. This study compares the clinical outcomes of TAVR between patients with a history of C-XRT and those without prior radiation exposure (control group). Methods: Patients with prior chest radiation therapy (C-XRT) were compared to a control group without radiation exposure to evaluate key clinical endpoints. For each endpoint, odds ratios (OR) and 95% confidence intervals (CI) were determined, and heterogeneity was analyzed using the I² statistic. A p-value of <0.05 was considered statistically significant. Results: Nine studies were included in the meta-analysis, encompassing 3083 C-XRT and 8891 control patients. Patients with prior C-XRT showed significantly higher long-term mortality (OR 1.84, 95% CI [1.08, 3.13], p=0.02) compared to controls. Other outcomes, including access-related vascular complications, Acute Kidney Injury, Congestive heart failure, major bleeding, need for pacemaker, short-term mortality, and stroke, did not demonstrate significant differences between the groups. Conclusions: Cancer survivors with prior chest radiation therapy undergoing TAVR may experience higher long-term mortality compared to patients without radiation exposure. However, no significant differences were observed in other major outcomes. These findings suggest that while TAVR is a viable treatment for C-XRT patients, long-term risks require further investigation to optimize patient selection and management strategies. Outcomes. Outcome OR 95% Confidence Interval P value Access related vascular complications 1.12 [0.85, 1.48] 0.43 Acute kidney injury 0.54 [0.20, 1.50] 0.24 Congestive heart failure 1.38 [0.88, 2.17] 0.16 Long term mortality 1.84 [1.08, 3.13] 0.02 Major bleeding 0.96 [0.78, 1.17] 0.67 Need for pacemaker 1.05 [0.88, 1.26] 0.57 Short term mortality 1.66 [0.97, 2.84] 0.06 Stroke 1.25 [0.74, 2.11] 0.39

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (12)

S

Saad Farooq

Montefiore Saint Luke's Cornwall Hospital, Newburgh, NY

M

Muneeb Khawar

King Edward Medical University, Lahore, Pakistan

U

Umad Ali

King Edward Medical University, Lahore, Pakistan

S

Syed Abdullah Shah

M

Mirza Muhammad Hadeed khawar

Services Institute of Medical Sciences, Lahore, Pakistan

A

Awon Muhammad

King Edward Medical University, Lahore, Pakistan

H

Hannan Saeed

KEMU, Lahore, Pakistan

S

Sardar Muhammad Imran Khan

NUMS, Rawalpindi , Pakistan

A

Abdul Qadeer

M

Mobeen Zaka Haider

West Virginia University, Morgantown, WV

M

Mohammad Hamza

Albany Medical Center, Aldan, Pennsylvania, United States

R

Robert W. Kirchoff

Mayo Clinic Hospital, Pheonix, AZ